Cargando…

Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population

BACKGROUND: Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast majority of FH remains undiagnosed in Latvia. The identification and early treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Radovica-Spalvina, Ilze, Latkovskis, Gustavs, Silamikelis, Ivars, Fridmanis, Davids, Elbere, Ilze, Ventins, Karlis, Ozola, Guna, Erglis, Andrejs, Klovins, Janis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587402/
https://www.ncbi.nlm.nih.gov/pubmed/26415676
http://dx.doi.org/10.1186/s12881-015-0230-x
_version_ 1782392480368427008
author Radovica-Spalvina, Ilze
Latkovskis, Gustavs
Silamikelis, Ivars
Fridmanis, Davids
Elbere, Ilze
Ventins, Karlis
Ozola, Guna
Erglis, Andrejs
Klovins, Janis
author_facet Radovica-Spalvina, Ilze
Latkovskis, Gustavs
Silamikelis, Ivars
Fridmanis, Davids
Elbere, Ilze
Ventins, Karlis
Ozola, Guna
Erglis, Andrejs
Klovins, Janis
author_sort Radovica-Spalvina, Ilze
collection PubMed
description BACKGROUND: Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast majority of FH remains undiagnosed in Latvia. The identification and early treatment of affected individuals remain a challenge worldwide. Most cases of FH are caused by mutations in one of four genes, APOB, LDLR, PCSK9, or LDLRAP1. The spectrum of disease-causing variants is very diverse and the variation detection panels usually used in its diagnosis cover only a minority of the disease-causing gene variants. However, DNA-based tests may provide an FH diagnosis for FH patients with no physical symptoms and with no known family history of the disease. Here, we evaluate the use of targeted next-generation sequencing (NGS) to identify cases of FH in a cohort of patients with coronary artery disease (CAD) and individuals with abnormal low-density lipoprotein–cholesterol (LDL–C) levels. METHODS: We used targeted amplification of the coding regions of LDLR, APOB, PCSK9, and LDLRAP1, followed by NGS, in 42 CAD patients (LDL–C, 4.1–7.2 mmol/L) and 50 individuals from a population-based cohort (LDL–C, 5.1–9.7 mmol/L). RESULTS: In total, 22 synonymous and 31 nonsynonymous variants, eight variants in close proximity (10 bp) to intron–exon boundaries, and 50 other variants were found. We identified four pathogenic mutations (p.(Arg3527Gln) in APOB, and p.(Gly20Arg), p.(Arg350*), and c.1706–10G > A in LDLR) in seven patients (7.6 %). Three possible pathogenic variants were also found in four patients. CONCLUSION: NGS-based methods can be used to detect FH in high-risk individuals when they do not meet the defined clinical criteria. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-015-0230-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4587402
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45874022015-09-30 Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population Radovica-Spalvina, Ilze Latkovskis, Gustavs Silamikelis, Ivars Fridmanis, Davids Elbere, Ilze Ventins, Karlis Ozola, Guna Erglis, Andrejs Klovins, Janis BMC Med Genet Research Article BACKGROUND: Familial hypercholesterolemia (FH) is one of the commonest monogenic disorders, predominantly inherited as an autosomal dominant trait. When untreated, it results in early coronary heart disease. The vast majority of FH remains undiagnosed in Latvia. The identification and early treatment of affected individuals remain a challenge worldwide. Most cases of FH are caused by mutations in one of four genes, APOB, LDLR, PCSK9, or LDLRAP1. The spectrum of disease-causing variants is very diverse and the variation detection panels usually used in its diagnosis cover only a minority of the disease-causing gene variants. However, DNA-based tests may provide an FH diagnosis for FH patients with no physical symptoms and with no known family history of the disease. Here, we evaluate the use of targeted next-generation sequencing (NGS) to identify cases of FH in a cohort of patients with coronary artery disease (CAD) and individuals with abnormal low-density lipoprotein–cholesterol (LDL–C) levels. METHODS: We used targeted amplification of the coding regions of LDLR, APOB, PCSK9, and LDLRAP1, followed by NGS, in 42 CAD patients (LDL–C, 4.1–7.2 mmol/L) and 50 individuals from a population-based cohort (LDL–C, 5.1–9.7 mmol/L). RESULTS: In total, 22 synonymous and 31 nonsynonymous variants, eight variants in close proximity (10 bp) to intron–exon boundaries, and 50 other variants were found. We identified four pathogenic mutations (p.(Arg3527Gln) in APOB, and p.(Gly20Arg), p.(Arg350*), and c.1706–10G > A in LDLR) in seven patients (7.6 %). Three possible pathogenic variants were also found in four patients. CONCLUSION: NGS-based methods can be used to detect FH in high-risk individuals when they do not meet the defined clinical criteria. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12881-015-0230-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-28 /pmc/articles/PMC4587402/ /pubmed/26415676 http://dx.doi.org/10.1186/s12881-015-0230-x Text en © Radovica-Spalvina et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Radovica-Spalvina, Ilze
Latkovskis, Gustavs
Silamikelis, Ivars
Fridmanis, Davids
Elbere, Ilze
Ventins, Karlis
Ozola, Guna
Erglis, Andrejs
Klovins, Janis
Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title_full Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title_fullStr Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title_full_unstemmed Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title_short Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL–C levels in a latvian population
title_sort next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased ldl–c levels in a latvian population
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587402/
https://www.ncbi.nlm.nih.gov/pubmed/26415676
http://dx.doi.org/10.1186/s12881-015-0230-x
work_keys_str_mv AT radovicaspalvinailze nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT latkovskisgustavs nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT silamikelisivars nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT fridmanisdavids nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT elbereilze nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT ventinskarlis nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT ozolaguna nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT erglisandrejs nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation
AT klovinsjanis nextgenerationsequencingbasedidentificationoffamilialhypercholesterolemiarelatedmutationsinsubjectswithincreasedldlclevelsinalatvianpopulation